Market closed
DexCom/$DXCM
DexCom shares are trading lower after the company received an FDA warning letter citing issues with its G6 and G7 sensor manufacturing.
12 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About DexCom
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Ticker
$DXCM
Sector
Trading on
Industry
Health Care Equipment & Supplies
Headquarters
Employees
10,250
Website
DexCom Metrics
BasicAdvanced
$27B
47.85
$1.42
1.29
-
Price and volume
Market cap
$27B
Beta
1.29
52-week high
$141.99
52-week low
$62.34
Average daily volume
4.2M
Financial strength
Current ratio
1.467
Quick ratio
1.223
Long term debt to equity
61.923
Total debt to equity
120.275
Interest coverage (TTM)
31.58%
Management effectiveness
Return on assets (TTM)
6.15%
Return on equity (TTM)
27.63%
Valuation
Price to earnings (TTM)
47.85
Price to revenue (TTM)
6.65
Price to book
12.66
Price to tangible book (TTM)
13.47
Price to free cash flow (TTM)
42.524
Growth
Revenue change (TTM)
11.34%
Earnings per share change (TTM)
9.35%
3-year revenue growth (CAGR)
18.10%
3-year earnings per share growth (CAGR)
38.81%
What the Analysts think about DexCom
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for DexCom stock.
DexCom Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
DexCom Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
DexCom News
AllArticlesVideos
Dexcom Schedules First Quarter 2025 Earnings Release and Conference Call for May 1, 2025 at 4:30 p.m. Eastern Time.
Business Wire·19 hours ago
Government of Saskatchewan Expands Public Coverage for Dexcom Continuous Glucose Monitoring Systems
Business Wire·3 days ago
Nanowear Announces Continuous Glucose Monitoring (CGM) Licensing and Data Partnership With Dexcom
Business Wire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for DexCom stock?
DexCom (DXCM) has a market cap of $27B as of April 04, 2025.
What is the P/E ratio for DexCom stock?
The price to earnings (P/E) ratio for DexCom (DXCM) stock is 47.85 as of April 04, 2025.
Does DexCom stock pay dividends?
No, DexCom (DXCM) stock does not pay dividends to its shareholders as of April 04, 2025.
When is the next DexCom dividend payment date?
DexCom (DXCM) stock does not pay dividends to its shareholders.
What is the beta indicator for DexCom?
DexCom (DXCM) has a beta rating of 1.29. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.